Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
| Index | ROBO Global Healthcare Technology and Innovation |
| Investment focus | Equity, World, Health Care |
| Fund size | EUR 181 m |
| Total expense ratio | 0.49% p.a. |
| Replication | Physical (Full replication) |
| Legal structure | ETF |
| Strategy risk | Long-only |
| Sustainability | Yes |
| Fund currency | USD |
| Currency risk | Currency unhedged |
| Volatility 1 year (in EUR) | 60.32% |
| Inception/ Listing Date | 2 July 2019 |
| Distribution policy | Accumulating |
| Distribution frequency | - |
| Fund domicile | Ireland |
| Fund Provider | Legal & General (LGIM) |
| Fund Structure | Public Limited Company |
| UCITS compliance | Yes |
| Administrator | BNY Mellon Fund Services (Ireland) Designated Activity Company |
| Investment Advisor | Legal & General Investment Management Limited |
| Custodian Bank | BNY Mellon Trust Company (Ireland) Limited |
| Revision Company | Ernst & Young |
| Fiscal Year End | 30 June |
| Swiss representative | State Street Bank International GmbH, Munich, Zurich Branch |
| Swiss paying agent | Skandinaviska Enskilda Banken AB (publ) |
| Germany | 30% tax rebate |
| Switzerland | ESTV Reporting |
| Austria | Tax Reporting Fund |
| UK | UK Reporting |
| Indextype | Total return index |
| Swap counterparty | - |
| Collateral manager | BNY Mellon Fund Services (Ireland) Limited |
| Securities lending | No |
| Securities lending counterparty |
| Arrowhead Pharmaceuticals | 2.28% |
| Grail | 2.17% |
| AxoGen | 2.14% |
| Thermo Fisher Scientific | 2.12% |
| Tempus AI, Inc. | 2.12% |
| Danaher Corp. | 2.06% |
| Guardant Health, Inc. | 2.00% |
| Vertex Pharmaceuticals | 1.94% |
| IQVIA Holdings | 1.92% |
| NovoCure | 1.92% |
| Health Care | 88.46% |
| Consumer Discretionary | 2.72% |
| Technology | 1.43% |
| Other | 7.40% |
| Broker | Rating | Execution fee | Account fee | |
|---|---|---|---|---|
| 0.00€ | 0.00€ | View offer* | |
| 0.00€ | 0.00€ | View offer* |
| YTD | +11.66% |
| 1 month | +0.55% |
| 3 months | +19.91% |
| 6 months | +27.79% |
| 1 year | +10.13% |
| 3 years | +14.86% |
| 5 years | -13.49% |
| Since inception (MAX) | +47.13% |
| 2024 | +9.53% |
| 2023 | -6.26% |
| 2022 | -29.18% |
| 2021 | +8.52% |
| Volatility 1 year | 60.32% |
| Volatility 3 years | 38.29% |
| Volatility 5 years | 34.46% |
| Return per risk 1 year | 0.17 |
| Return per risk 3 years | 0.12 |
| Return per risk 5 years | -0.08 |
| Maximum drawdown 1 year | -40.47% |
| Maximum drawdown 3 years | -40.47% |
| Maximum drawdown 5 years | -50.89% |
| Maximum drawdown since inception | -50.89% |
| Listing | Trade Currency | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
|---|---|---|---|---|---|
| gettex | EUR | XMLH | - - | - - | - |
| Borsa Italiana | EUR | DOCT | DOCT IM DOCEURIV | LGDOCT.MI DOCTEURINAV=SOLA | Flow Traders B.V. |
| London Stock Exchange | GBX | DOCG | DOCG LN NA | DOCG.L NA | Flow Traders B.V. |
| London Stock Exchange | USD | DOCT | DOCT LN NA | DOCT.L NA | Flow Traders B.V. |
| SIX Swiss Exchange | CHF | DOCT | DOCT SW DOCEURIV | DOCT.S | Flow Traders B.V. |
| XETRA | EUR | XMLH | XMLH GY DOCEURIV | DOCT.DE | Flow Traders B.V. |
| Fund name | Fund Size in m € (AuM) | TER p.a. | Distribution | Replication |
|---|---|---|---|---|
| iShares Healthcare Innovation UCITS ETF | 887 | 0.40% p.a. | Accumulating | Sampling |
| L&G Pharma Breakthrough UCITS ETF | 17 | 0.49% p.a. | Accumulating | Full replication |
| VanEck Genomics and Healthcare Innovators UCITS ETF A | 14 | 0.35% p.a. | Accumulating | Full replication |
| Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C 1C | 6 | 0.30% p.a. | Accumulating | Full replication |